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9 YEAR OLD GIRL WITH PROGRESSIVE WEAKNESS
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CLINICAL HISTORY

MICROSCOPIC PATHOLOGY

A 9-year old girl presented with a 6 month history of progressive
shoulder and back discomfort associated with generalized weakness and exercise intolerance.
Her past medical history was complicated by spina bifida in
association with a Chiari type II malformation and hydrocephalus.
She had undergone a myelomeningocele repair, tethered cord
release and placement of a VP shunt. Developmental motor milestones were delayed (walking began at age 2) but she eventually
walked unassisted. She had mild bowel and bladder dysfunction.
On physical exam, muscle bulk and tone were normal in the
upper limbs but shoulder adduction was weak, graded 4/5. Shoulder abduction and elbow flexion were graded 4+/5. Muscle bulk in
the lower limbs was decreased. Tone was normal. Hip flexion and
knee flexion were graded as 4+/5. When asked to lie supine then
rise to a standing position she demonstrated a partial Gower’s
maneuver.
Nerve conduction studies were normal, but electromyography
demonstrated myopathic units in the shoulder girdle muscles and
quadriceps. A muscle biopsy was performed.

Perimysial and endomysial connective tissues were found to be
generous and fibre size variation was markedly increased on the
basis of scattered hypertrophic and atrophic fibres. Individual and
small clusters of degenerating and regenerating fibres were present
and associated with light adjacent mononuclear infiltrates. Internal
nuclei were increased and scattered rounded, hypereosinophilic
(hypercontracted) fibres were present.
Dystrophin immunohistochemistry (N-terminus, rod domain
and C-terminus) identified a highly variable expression pattern
from fibre to fibre with approximately half of the fibres showing
normal expression and the remainder having markedly reduced,
patchy or no expression. Dystrophin expression levels were highly
variable from fascicle to fascicle. Figure 1 shows the skeletal
muscle biopsy reveals endomysial and perimysial fibrosis and
increased fiber size variation. Internal nuclei are increased in frequency and there centrally in the field of view are degenerating and
regenerating fibers, while Figure 2 shows scattered hyperstaining,
rounded (hypercontracted) fibers. Figure 3 shows spectrin immunostains and in figure 4 immunostains for dystrophin were used.
What is the diagnosis?
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Figure 2.
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DIAGNOSIS
Manifesting carrier of a dystrophinopathy.
She has a duplication noted in exon 5–11 of the dystrophin gene.
Her X-inactivation studies showed marked skewing, with 95%
inactivation of the wild-type allele.

DISCUSSION
The present case is an uncommon example of a manifesting Duchenne carrier presenting with myalgias and proximal muscle weakness. Although symptomatic pediatric cases are rare, there are
several reported cases of manifesting female Duchenne Muscular
Dystrophy (DMD) and Becker’s Muscular Dystrophy (BMD) carriers presenting between 20 and 40 years of age. Typically the such
cases have mild proximal weakness and dilated cardiomyopathy
(4). Muscular weakness can be demonstrated in 19% of female
DMD carriers and 14% of female BMD carriers (3). Myalgia and
muscle cramps, however, are only present in 4–7% of this patient
group. Furthermore, the mean age of onset of symptoms in these
carriers is 33 years and signs do not tend to occur before age 16 (3).
There have been two previous case reports describing the presentations of young female dystrophinopathy carriers (2, 8). In
addition to skewed X-inactivation, there are several additional rare
circumstances in which a female carrier may manifest with earlier
and more severe dystrophy (1, 5, 7).
In our case, non-randomized X-inactivation or unfavourable
lyonization was the mechanism for marked dystrophin underexpression. X-inactivation is considered non-randomized or
“skewed” if 80% or more lymphocytes in the blood have the same
active X-chromosome (6). In one study all female manifesting
carriers studied showed skewed X-inactivation while all unaffected
carriers studied showed symmetrical X-inactivation (10). However,
there are examples where symptomatic patients do not display
significant X-inactivation (2). The gold standard for diagnosis
remains immunostaining for dystrophin with a mosaic distribution
of positive and negative fibers in both cardiac and skeletal muscles.
However, immunostaining has not been shown to correlate accurately with the severity of diseases(4, 9). While predicting progression is difficult, diagnosis is essential to genetic counseling. (The
full text for this discussion can be found at: http://path.upmc.edu/
divisions/neuropath/bpath/cases/case190/dx.html).
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ABSTRACT
A 9-year-old female patient experienced progressive weakness and
myalgias of shoulders and back of several months duration. Her
medical history was notable for spina bifida in association with a
Chiari type II malformation and hydrocephalus. Developmental
motor milestones were delayed whereby walking began at age 2.
She had mild bowel and bladder dysfunction. At presentation, her
neurological exam was notable for weak shoulder adduction, hip
and knee flexion and she demonstrated a partial Gower’s maneuver.
A muscle biopsy showed dystrophic changes and immunohistochemical findings of a Duchenne’s mosaic which was
confirmed by DNA analysis. The proposed pathogenesis in this
case is unfavourable lyonization, which was corroborated by
X-inactivation studies.
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